Search

Your search keyword '"Tovazzi, Valeria"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Tovazzi, Valeria" Remove constraint Author: "Tovazzi, Valeria"
35 results on '"Tovazzi, Valeria"'

Search Results

2. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

3. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

4. Merkel Cell Carcinoma

5. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

6. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

10. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

11. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

12. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

14. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

15. Clinical and pathological prognostic factors in Merkel cell carcinoma.

16. Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.

17. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

18. Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic

20. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

21. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

22. Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

23. Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

24. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

25. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

26. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

27. The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures

28. A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report

30. Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review

31. Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review.

32. Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial

33. The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

34. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

35. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.

Catalog

Books, media, physical & digital resources